The CLEOPATRA trial reported the survival benefit of pertuzumab with trastuzumab plus docetaxel in HER2-positive metastatic breast cancer patients. However, there are a few case reports concerning the effects of a pertuzumab-containing regimen on brain metastases. A 55-year-old woman, who underwent curative surgery for breast cancer after neoadjuvant chemotherapy 5 years previously, developed repeated solitary brain metastasis in her right occipital lobe. Whole brain radiation therapy, stereotactic radiosurgery and 3 times of surgical resection were performed. Lapatinib and capecitabine plus tamoxifen were administered. The metastasis recurred in the stump of the previous surgery. Pertuzumab with trastuzumab plus docetaxel was initiated as second-line chemotherapy. A complete response of the brain metastasis was achieved, which persisted for 5 months. Pertuzumab with trastuzumab plus docetaxel was effective in reducing the brain metastases from breast cancer. Further studies are warranted to confirm the effect of this regimen on brain metastases.

No abstract

No abstract

No abstract

Abstract.A recent investigation has indicated that reactive oxygen species (ROS) may play an important role in the activation of lymphocytes. The main aim of the present study is to find out what effect on lymphocyte activation is attributable to radical scavengers (RSs). AD0261 (AD) is a novel RS which displays strong inhibitory action on the generation of lipid peroxides and superoxide anions. This compound has been shown to be effective in inhibiting tritiated thymidine ([3H]TdR) incorporation into, IL-2 release from and IL-2 receptor (Rc) expression on Con A-stimulated mouse spleen cells and PHA-Pstimulated lymphocytes of human peripheral blood, IC50 values being in the range 1-10 gM. It also inhibited erythema formation elicited by transferring PHA-Pstimulated lymphocytes into guinea pigs (30-40% inhibition at 10 gM, p<0.05). Further study showed that the activity of ornithine decarboxylase (ODC), which is a critical enzyme for cell proliferation, was inhibited by AD in a dose-dependent manner (IC50 = 1.0 gM). In summary, AD would seem to affect the lymphocyte activation by inhibiting ODC activity, probably through the action of ROS trapping.